midostaurin
midostaurin: sourced relationships with 1 company · 2 clinical trials tracked · 1 FDA decision.
midostaurin evidence translation
What we can confirm
1 FDA record · 2 tracked trials
What it means
What to watch
Prepared research question
How could midostaurin → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| Novartis AG (NVS) Reported 2017-04-28 · Current development: unknownSource | Approved |
| Novartis AG (NVS) Reported 2017-04-28 · Current development: unknownSource FLT3-mutated Acute Myeloid Leukemia | Phase 2 |
| Novartis AG (NVS) Reported 2017-04-28 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (2)
A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML
Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicity (DLT)
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutated AML
Primary endpoint: Part 1 of the study: Occurence of dose limiting toxicities (DLT)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with midostaurin?
midostaurin has dated SEC/FDA relationship records for Novartis AG.
How many clinical trials involve midostaurin?
BioSniper tracks 2 clinical trials involving midostaurin.
What is midostaurin's latest FDA decision?
The most recent tracked FDA decision for midostaurin is Approval, dated April 28, 2017.